Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants

Trial Profile

Direct acting antiviral therapy of hepatitis C in Denmark: treatment response, adverse events and resistance associated variants

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Mar 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Dasabuvir; Ledipasvir/sofosbuvir; Ombitasvir/paritaprevir/ritonavir; Ribavirin; Sofosbuvir
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Mar 2017 Planned number of patients changed from 11 to 111.
    • 01 Dec 2016 Planned number of patients changed from 222 to 11.
    • 01 Dec 2016 Planned End Date changed from 9 Jun 2017 to 9 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top